Evaluation of the possible benefits of post-radiotherapy surgery after concomitant chemoradiotherapy with a new radio-sensitizing regimen (irinotecan / CPT-11, interferon A2b and amifostine) for advanced-stage cervical carcinoma. Preliminary results of a pilot phase-II study

Journal of B.U.ON.

Volumn 14, Issue 2, 2009, Pages 197-202

  Vorgias, George ^a,c   Profitis, E ^a   Sarris, G ^a   Strigou, S ^b   Kosmas, C ^a   Katsoulis, M ^a   Karamoussa, E ^a   Kalinoglou, N ^a   Koliarakis, N ^a   Dertimas, B ^a   Bafaloukos, D ^a   Akrivos, T ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b INEGSEE Institute   (Greece)

^c NONE   (Greece)

Author keywords

Advanced stage cervical carcinoma; Amifostine; Chemoradiotherapy; Interferon; Irinotecan; Post radiotherapy surgery

Indexed keywords

ALPHA2B INTERFERON; AMIFOSTINE; IRINOTECAN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MORBIDITY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE COMPLICATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 67651009192     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-1143. (Pubitemid 29177872)
2. Whitney CW, Sause W, Bundt BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999; 17: 1339-1348. (Pubitemid 29220838)
3. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 15: 1144-1153. (Pubitemid 29177873)
4. Pearcey R, Brundage M, Drouin P et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20: 966-972. (Pubitemid 34141839)
5. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta- analysis. Lancet 2001; 358: 781-786. (Pubitemid 32868726)
6. Waggoner SE. Cervical cancer. Lancet 2003; 361: 2217-2225.
7. Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modem management of locally advanced cervical carcinoma. Cancer Treat Rev 2003; 29: 389-399. (Pubitemid 37185105)
8. Lukka H, Hirte H, Fyles A et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer - a meta- analysis. Clin Oncol (R Coll Radiol) 2002; 14: 203-212. (Pubitemid 34906024)
9. Jemal A, Murray T, Ward E et al. Cancer statistics. CA Cancer J Clin 2005; 55: 10-30.
10. Grigsby PW. Cervical cancer: combined modality therapy. Cancer J 2001; (Suppl 1): 47-50.
11. Sarris G, Pectasides D, Kalinoglou N et al. Efficacy and safety of combined radiotherapy with irinotecan (CPT-11), interferon (INF-alpha-2b) and amifostine in patients with locally advanced cervical carcinoma. Eur J Cancer 2005; 3: 275 (abstr).
12. Lhomme C, Fumoleau P, Fargeot P et al. Results of a European Organization for Research and Treatment of Cancer / Early Clinical studies group Phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999; 17: 3136-3142. (Pubitemid 29470643)
13. Tanaka K, Kokawa K, Umesaki N. Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study. Eur J Gynaecol Oncol 2005; 26: 605-607. (Pubitemid 43028052)
14. Verastegui-Aviles E, Mohar A, Mota A, De La Garza-Salazar J. Combination of radiation therapy and interferon alpha-2b in patients with advanced cervical carcinoma: A pilot study. Int J Gynecol Cancer 1999; 9: 401-405.
15. Small W Jr. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial. Semin Oncol 2003; 30(6 Suppl 18): 68-71.
16. De Los Santos JF, Small W. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG 0116 and review of future directions. Semin Oncol 2004; 31(6 Suppl 18): 37-41.
17. DiStefano M, Fagotti A, Ferrandina G et al. Preoperative chemo-radiotherapy in locally advanced cervical cancer: Long-term outcome and complications. Gynecol Oncol 2005; 99(5 Suppl 3): 166-170.
18. Houvenaeghel G, Lelievre L, Gonzague-Casabianca L et al. Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol 2006; 100: 338-343. (Pubitemid 43075266)
19. Classe JM, Morice P, Rodier J. Pathological evaluation of pelvic radiotherapy with concurrent cisplatin-based chemotherapy followed by surgery in treatment of locally advanced cervical cancer: a retrospective multicentric experience of French Federation of Cancer Centres. Eur J Surg Oncol 2002; 28: 1 (abstr).
20. Houvenaeghel G, Lelievre L, Rigouard AL et al. Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecol Oncol 2006; 102: 74-79. (Pubitemid 43851056)
21. Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE. Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIb cervical carcinoma. Int J Clin Oncol 2004; 9: 120-124.